Serum cytokines and bone metabolic markers in patients with rheumatoid arthritis treated with biological disease modifying anti-rheumatic drugs

ConclusionsbDMARDs with different modes of action exert different effects on the cytokine and bone metabolic marker levels in patients with RA.Key Points• While clinical effectiveness is comparable with infliximab, tocilizumab, and abatacept in patients with rheumatoid arthritis, changes in cytokine and bone metabolic marker levels are distinct among bDMARDs.• Especially, changes in interferon-γ, tumor necrosis factor-α levels with infliximab, interleukin-6, bone-specific alkaline phosphatase, osteocalcin levels with tocilizumab, and interleukin-1β, interleukin-8 levels with abatacept are significant.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research